Caris Life Sciences, Inc.
CAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.87 | -0.00 | 0.00 | 0.79 |
| FCF Yield | 0.65% | 0.34% | -0.48% | -0.92% |
| EV / EBITDA | 238.31 | -31.07 | -90.90 | 0.00 |
| Quality | ||||
| ROIC | 3.63% | 2.06% | -29.70% | 0.00% |
| Gross Margin | 0.00% | 62.67% | 47.19% | 37.54% |
| Cash Conversion Ratio | 2.57 | -0.10 | 0.31 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.08% | 10.30% | 1.19% | -4.25% |
| Free Cash Flow Growth | 837.48% | 117.35% | 0.00% | 13.41% |
| Safety | ||||
| Net Debt / EBITDA | -23.12 | 6.50 | -4.70 | 0.00 |
| Interest Coverage | -2.42 | 0.94 | -4.53 | 4.90 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.67 | 1.75 | 0.00 |
| Cash Conversion Cycle | 11.08 | 41.05 | 77.05 | 0.00 |